Immunocore Holdings plc Other Comprehensive Income Net Of Tax Exchange Differences On Translation
Immunocore Holdings plc (IMCR) reported Other Comprehensive Income Net Of Tax Exchange Differences On Translation of GBP 1.05 million for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Income Statement › Unrealized Gains
ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation · last filed 2023-08-10
- Immunocore Holdings plc other comprehensive income net of tax exchange differences on translation for the quarter ending 2023-06-30 was 1.05M GBP.
- Immunocore Holdings plc other comprehensive income net of tax exchange differences on translation for the quarter ending 2022-12-31 was -1.34M GBP, a 7533.33% decline year-over-year.
- Immunocore Holdings plc other comprehensive income net of tax exchange differences on translation for the quarter ending 2022-09-30 was -1.73M GBP.
- Immunocore Holdings plc other comprehensive income net of tax exchange differences on translation for the quarter ending 2022-06-30 was -323.00K GBP.
| Period end | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 3 month | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 6 month | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 9 month | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 12 month |
|---|---|---|---|---|
| 2023-06-30 | 1.05M GBP 6-K · filed 2023-08-10 | 1.43M GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | -1.34M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -3.07M GBP derived: sum of 2 quarters · filed 2023-03-01 | -3.39M GBP derived: sum of 3 quarters · filed 2023-08-10 | -3.19M GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | -1.73M GBP 6-K/A · filed 2022-11-18 | -2.05M GBP derived: sum of 2 quarters · filed 2023-08-10 | -1.85M GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | -323.00K GBP 6-K · filed 2023-08-10 | -118.00K GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | 18.00K GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -20.00K GBP derived: sum of 2 quarters · filed 2023-03-01 | -74.00K GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | -38.00K GBP 6-K/A · filed 2022-11-18 | -92.00K GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | 195.00K GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | -99.00K GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | 72.00K GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |